Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance

Pfizer’s BRAFTOVI combo doubles progression-free survival in aggressive colorectal cancer trial

The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival

Pantherna acquisition to boost T-CURX’s clinical translation of non-viral In Vivo CAR-T strategies

Proprietary technologies in LNP-based delivery of mRNA and DNA vectors to advance T-CURX innovative in vivo CAR-T assets into clinical trials one year earlier

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer

Glenmark posts strong FY26 results with 27.5% revenue jump

AstraZeneca reports mixed Phase III results for anselamimab in rare cardiac amyloidosis trial

The programme evaluated anselamimab as a first-line add-on to standard plasma cell dyscrasia therapy in patients with advanced cardiac AL amyloidosis

Lupin secures FDA nod for generic Sutab tablets with 180-day exclusivity

The approved product is the generic equivalent of Sutab® Tablets developed by Azurity Pharmaceuticals

Fermenta Biotech reports 26% revenue growth in FY26

Alkem Labs posts highest-ever EBITDA in FY26; Q4 revenue rises 14.6%

Strong domestic and international growth, improving product mix, and operational efficiencies drive margin expansion despite exceptional charges impacting quarterly profit

Lupin's novel cancer therapy LNP8701 shows encouraging results in phase 1 trial

First-in-human study of investigational SOS1 inhibitor shows encouraging safety profile and early anti-tumor activity in patients with metastatic solid tumors